Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03527212 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease
A Phase 3 study, sponsored by Senju Pharmaceutical Co..
- Completed
- Registry status
- Phase 3
- Development phase
- 329
- Enrollment target
NCT03527212 is a Phase 3 study that has completed, run by Senju Pharmaceutical Co.. The registered enrollment target is 329 participants.
The verdict
NCT03527212, a Phase 3 study, has completed, sponsored by Senju Pharmaceutical Co..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 329 participants
- Enrollment target
Study Summary
A double-masked, randomized, multi-center, placebo-controlled, parallel-group study in adult patients with Dry Eye Disease (DED). Patients will be randomly assigned to receive either SJP-0035 0.001% or placebo
Interventions
- DRUG Placebo
- DRUG SJP-0035 0.001%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 329 participants |
| Start Date | 2018-08-20 |
| Est. Completion | 2019-03-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03527212
The ClinicalTrials.gov registry entry for NCT03527212 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 329 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Senju Pharmaceutical Co., which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03527212 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03527212 about?
NCT03527212 is a clinical study titled "A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease". A double-masked, randomized, multi-center, placebo-controlled, parallel-group study in adult patients with Dry Eye Disease (DED). Patients will be randomly assigned to receive either SJP-0035 0.001% or placebo
What is the current status of trial NCT03527212?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 329 participants. The study started on 2018-08-20. Estimated completion is 2019-03-15.
What interventions are being tested in trial NCT03527212?
The interventions under investigation include: Placebo (DRUG), SJP-0035 0.001% (DRUG).
Who is sponsoring clinical trial NCT03527212?
This trial is sponsored by Senju Pharmaceutical Co., which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.